We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
26 Mar 2024 - Increasing manufacturing volume requirements and the high process mass intensity (PMI) of peptide synthesis warrants continued industry efforts for more sustainable production processes. PolyPeptide collaborated with […]
Read more19 Mar 2024 - Baar, 19 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, published today the invitation to […]
Read more12 Mar 2024 - Baar, 12 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]
Read more22 Feb 2024 - Org. Process Res. Dev. 2024, 28, 652–660 Ashley, M. A.; Aukland, M. H.; Bryan, M. C.; Cismesia, M. A.; Dutschei, T.; Engl, O. D.; Engl, P. […]
Read more31 Oct 2023 - Strasbourg, 31 October 2023 – PolyPeptide today announced the signing of a collaboration agreement with the Peptide Sciences Laboratory of the University of KwaZulu-Natal (UKZN) in […]
Read more2 Oct 2023 - Baar, 2 October 2023 – PolyPeptide Group AG (SIX: PPGN) announces the signing of a revolving credit facility agreement with Credit Suisse, Danske Bank and Zürcher […]
Read more13 Sep 2023 - Org. Process Res. Dev. 2023, 27, 1858–1867 Ashley, M. A.; Aukland, M. H.; Bryan, M. C.; Cismesia, M. A.; Engl, O. D.; Engl, P. S.; Garcia, […]
Read more15 Aug 2023 - Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO: Reported results […]
Read more13 Jul 2023 - Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide […]
Read more